The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
The liver diseases of lipodystrophy: The long-term effect of leptin treatment
Open accessAbstract
Background & Aims Lipodystrophies are hypoleptinemic conditions characterized by fat loss, severe insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. Nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are also features of this condition. We studied the spectrum of liver disease in lipodystrophy and the effects of leptin replacement. Methods This was an open-label prospective study of leptin therapy in patients with inherited and acquired lipodystrophy at the National Institutes of Health. Liver biopsies were performed at baseline (N=50) and after leptin replacement (N=27). NASH activity was assessed using the NASH Clinical Research Network (CRN) scoring system. Fasting blood glucose, triglyceride, hemoglobin A1c and liver enzymes were measured at baseline and at the time of the final liver biopsy. Results In leptin treated patients, 86% met criteria for NASH at baseline, while only 33% had NASH after leptin replacement for 25.8 ± 3.7 months (mean ± SE, p 0.0003). There were significant improvements in steatosis grade (reduction of mean score from 1.8 to 0.9) and ballooning injury scores (from 1.2 to 0.4), with a 44.2% reduction in mean NAFLD activity score (p < 0.0001). Patients who already had fibrosis remained stable on leptin replacement. We observed significant improvement in metabolic profile, ALT and AST. In addition to NASH, four patients with acquired generalized lipodystrophy (AGL) had autoimmune hepatitis. Conclusions The fundamental liver disease of lipodystrophy is NASH, although autoimmune hepatitis was observed in some patients with AGL. Leptin appears to be a highly effective therapy for NASH in hypoleptinemic lipodystrophic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“Biopsy specimens were scored prospectively by a single hepatopathologist (DEK), blinded to the clinical data and sequence of the biopsies, using the NASH CRN method [8].”
MethodSelf-citationNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341 · cited 1×
“There are mouse models expressing different features, but none which shows all the features of NASH [17–20].”
BackgroundLeptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228 · cited 2×
“We previously reported a preliminary study of the effect of recombinant human methionyl leptin (metreleptin, Amylin Pharmaceuticals, San Diego, CA) therapy in the treatment of NAFLD in lipodystrophy [5].”
BackgroundResultSelf-citationARIOGLU, E., ANDEWELT, A., DIABO, C., BELL, M., TAYLOR, S. I., & GORDEN, P. (2002) · Medicine · doi:10.1097/00005792-200203000-00001 · Cited by 223 · cited 1×
“This has been demonstrated in patients with insulin receptor mutations [15] or autoantibodies against the insulin receptor [16] who have extreme insulin resistance, but do not have ectopic fat deposition in the liver and do not develop metabolic liver disease.”
Background
Cited by
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“Severe NAFLD/NASH is a complication of congenital lipodystrophies (Safar Zadeh et al., 2013), in which the absence of adipose tissue forces the liver to store excess fatty acids, leading to severe insulin resistance (Kim et al., 2000; Petersen et al., 2002).”
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araujo-Vilar, D., Cheung, P. T., Dunger, D., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 529
Self-citationManagement of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Preclinical models of non-alcoholic fatty liver disease
Santhekadur, P. K., Kumar, D. P., & Sanyal, A. J. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.031 · Cited by 380
Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Brown, G. T., & Kleiner, D. E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.008 · Cited by 363
Self-citationAdipokines in nonalcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2015.11.006 · Cited by 348
Eslam, M., Alkhouri, N., Vajro, P., Baumann, U., Weiss, R., Socha, P., Marcus, C., Lee, W. S., Kelly, D., Porta, G., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00183-7 · Cited by 281
Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Hansen, H. H., Feigh, M., Veidal, S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.06.007 · Cited by 270
Congenital generalized lipodystrophies—new insights into metabolic dysfunction
Patni, N., & Garg, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.123 · Cited by 261
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235
Leptin applications in 2015: what have we learned about leptin and obesity?
Farr, O. M., Gavrieli, A., & Mantzoros, C. S. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000184 · Cited by 233
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Diagnosis and treatment of lipodystrophy: a step-by-step approach
Araújo-Vilar, D., & Santini, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0887-z · Cited by 194
20 YEARS OF LEPTIN: Leptin in common obesity and associated disorders of metabolism
DePaoli, A. M. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0258 · Cited by 86
Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD
Vilarinho, S., Ajmera, V., Zheng, M., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.32047 · Cited by 85
Effects of Metreleptin in Pediatric Patients With Lipodystrophy
Brown, R. J., Meehan, C. A., Cochran, E., Rother, K. I., Kleiner, D. E., Walter, M., & Gorden, P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3628 · Cited by 65
Self-citationAbulizi, A., Perry, R. J., Camporez, J. P. G., Jurczak, M. J., Petersen, K. F., Aspichueta, P., & Shulman, G. I. (2017) · The FASEB Journal · doi:10.1096/fj.201700001r · Cited by 41
Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives
Tchang, B. G., Shukla, A. P., & Aronne, L. J. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1052789 · Cited by 28
Brush, M., Auh, S., Cochran, E., Tuska, R., Koh, C., Kleiner, D. E., Lightbourne, M., & Brown, R. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae335 · Cited by 10
Self-citation
Metadata
- Authors
- Safar Zadeh, E., Lungu, A. O., Cochran, E. K., Brown, R. J., Ghany, M. G., Heller, T., Kleiner, D. E., & Gorden, P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 59
- Issue
- 1
- Pages
- 131-137
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2052222168
- Cited by
- 165
- References
- 9
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.